(CIX: WRAL30)  1,102.96  up arrow+11.29  (1.03 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: Apple)  108.00  up arrow+1.02  (0.95 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: QUINTILES)  58.54  up arrow+2.24  (3.98 %)  Updated: 06:40 PM EDT, Oct 31 2014
(OP: BASF SE)  88.22  up arrow+1.3  (1.5 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: BioCryst)  11.72  down arrow-0.34  (-2.82 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: BioDelivery)  17.40  down arrow-0.39  (-2.19 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: CEMP)  13.60  down arrow-0.09  (-0.66 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: Cisco Systems)  24.47  up arrow+0.39  (1.62 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: Cree)  31.48  down arrow-0.03  (-0.1 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: DARA)  0.85  down arrow-0.03  (-3.3 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: EMC CORPORATION)  28.73  up arrow+0.27  (0.95 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Extreme Networks)  3.59  up arrow+0.06  (1.7 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: FB)  74.99  up arrow+0.88  (1.19 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: GLAXOSMITHKLINE)  45.49  up arrow+0.35  (0.78 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: GOOG)  559.08  up arrow+8.77  (1.59 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: IBM)  164.40  up arrow+0.05  (0.03 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NY: LH)  109.29  up arrow+1.9  (1.77 %)  Updated: 06:40 PM EDT, Oct 31 2014
(OP: Lenovo Group)  29.49  down arrow-0.07  (-0.24 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: MRK)  57.94  up arrow+0.63  (1.1 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Microsoft Corp)  46.95  up arrow+0.9  (1.95 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: NTAP)  42.80  up arrow+0.69  (1.64 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: NOVARTIS AG)  92.69  up arrow+0.74  (0.8 %)  Updated: 06:40 PM EDT, Oct 31 2014
(OP: Novozymes A/S)  46.30  down arrow-0.01  (-0.02 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: PFIZER)  29.95  up arrow+0.11  (0.37 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: Pozen)  9.07  down arrow-0.1  (-1.09 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NY: RED HAT)  58.92  up arrow+0.67  (1.15 %)  Updated: 06:40 PM EDT, Oct 31 2014
(NQ: BBRY)  10.50  up arrow+0.02  (0.19 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: Salix)  143.85  down arrow-0.65  (-0.45 %)  Updated: 08:10 PM EDT, Oct 31 2014
(NQ: SQI)  14.91  down arrow-2.02  (-11.93 %)  Updated: 08:10 PM EDT, Oct 31 2014

Posts tagged “Quintiles”

March 13

Premium Lock Quintiles lowers big stock offering by some $44M

Dennis Gillings, the co-founder of Quintiles, and other investors in the world's largest life science services company, won't be getting as much as expected from an offering of stock that cashes in on a 2013 IPO.

Dennis Gillings Dennis Gillings

Updated March 10

Premium Lock Gillings, Quintiles investors look to cash out $939M in shares

Dennis Gillings, the co-founder of Quintiles, and other investors in the world's largest life science services company, are looking to cash in on Quntiles' IPO from last year. According to an SEC filing made early Monday, they are offering some 17.5 million shares worth $939.3 million.

Dennis Gillings, center, rings in NYSE action Dennis Gillings, center, rings in NYSE action

February 14

Premium Lock In their own words: Quintiles execs praise Novella deal, look for more

Tom Pike An analyst quizzed Quintiles executives about the company's 2013 purchase of near-by Novella. CFO Kevin Gordon and CEO Tom Pike had plenty of good things to say, especially the financial performance. They also said Quintiles continues to look for more deals.

Updated February 13

Premium Lock Quintiles reports first $1B in quarterly service revenues

Quintiles' headquarters    Investors like the overall earnings report and forecast for the coming year. Shares climb in pre-market trading. Says Quintiles CEO Tom Pike. "We are well positioned entering 2014 with the largest backlog in the industry at $9.9 billion dollars which will fuel 2014 constant currency service revenue and earnings growth.

February 6

Premium Lock Quintiles report: Defining, achieving health care 'value' remains elusive

Quintiles says more cross-industry discussions involving all stakeholders - including patients - are needed to find ways to identify and deliver health care value. Read more about the findings from Quintiles' "Value is the Target" report.

Quintiles' Value is the Target report Quintiles' Value is the Target report

Updated January 15

Premium Lock Quintiles' tech security wins CSO magazine honor

Quintiles        Cisco, Credit Suisse and Metlife also crack the CSO list.

Updated January 14

Premium Lock Pill reminders, medication mix warnings go mobile through Quintiles app

Quintiles, the world's largest life science services company is now providing patient warnings and reminders about medication through a new mobile app.

Updated January 8

Premium Lock Quntiles puts its guard up as mobile medical alerts app rolls out

Quintiles offers a free website and now a mobile app to help people deal with personal health issues, but the company also is taking steps - including staff who monitor the site and news - in order to ensure safety and to protect itself from lawsuits. "Q" management has obviously learned the lesson of the bad guy in Magnificent Seven: No good deed goes unpunished.

A sample MediGuard alert A sample MediGuard alert

January 8

Premium Lock SAS to tout 'Big Ideas;' Sony TV service; Quintiles' new deal; Nortel settlement; Yahoo touts ads; Twitter co-founder's startup

Bulldog Our Bulldog blog wrapup of the latest technology news: SAS has big plans for the National Retail federation show; Sony plans Internet-based TV service; Quintiles strikes info deal with Georgia firm; judge OKs Nortel deal; Yahoo unveils new services; Twitter co-founder launches new photo app.

December 27, 2013

Premium Lock NFL knee injuries are down, Quintiles Outcome analysis finds

Outcome, a division of pharmaceutical services provider Quintiles isn't limited to drug studies. The company analyzed knee injuries for the NFL and found that ACL injuries are down so far this season.

Quintiles' headquarters    Quintiles' headquarters

Updated December 17, 2013

Premium Lock Quintiles denies treating Bhopal gas victims as 'guinea pigs'

India's health ministry tells that country's Supreme Court that Quintiles treated survivors of the 1984 Bhopal gas disaster as "guinea pigs" who volunteered to participate in two clinical trials for drugs. In two instances, Quintiles did not meet some standards, the government says. Quintiles denies the charges.

Quintiles' headquarters    Quintiles' headquarters

December 12, 2013

Premium Lock Quintiles names consulting exec to lead commercial services

Scott Evangelista W. Scott Evangelista, an executive at Deloitte Consulting, is taking over as president of Integrated Commercial Services at Quintiles. He replaces Rich Pilnik, who is retiring.

November 27, 2013

Premium Lock Quintiles insiders, private equity backers sell $94.7M worth of shares

Insiders and private equity backers of Quintiles sold nearly $95 million worth of stock in the company last week. So why are these sales happening now? WRALTechWire Insiders get the story.

Quintiles' headquarters    Quintiles' headquarters

Updated November 22, 2013

Premium Lock Another Quintiles executive unloads shares - $8.5 million worth

Quintiles        Michael Mortimer, executive vice president and chief administration officer, at Quintiles has sold shares worth more than $8 million. He's the second senior executive officer to do so in the past week.

November 22, 2013

Premium Lock Quintiles lands two top honors in global Scrip awards

Quintiles' headquarters    The world's largest lifer science company receives the top "Contract Research Organization" honor for the second consecutive year. Its Infosario Safety product wins the top honor for best technological development in clinical trials.

Updated November 20, 2013

Premium Lock Quintiles executive Ratliff cashes out $9M in stock ahead of departure

Quintiles executive John Ratliff is selling some of his stock in the biopharmaceutical services firm before he steps down at the end of the year. WRALTechWire Insiders can access the details.

John Ratliff John Ratliff

November 14, 2013

Premium Lock On World Diabetes Day, Quintiles MD warns the disease is 'an increasingly serious problem'

In observation of World Diabetes Day on Thursday, made available a video, an informational graphic and a host of other information that - collectively that warns about the increasing threat posed by the disease worldwide. Affecting 366 million people worldwide, diabetes also accounts for a big percentage of healthcare costs. In 2011, the percentage was 11 percent. Dr. Erica Caveney of Quintiles discusses the state of the global fight - and what she feels is a bright future for diabetes patients.

The global scourge of diabetes The global scourge of diabetes

October 31, 2013

Premium Lock Quintiles reveals details of Novella acquisition; value climbs if revenue, business targets hit

Novella Clinical, a Quintiles acquisition focused on oncology and medical devices, has financial incentives to grow that business for its new parent. Learn how much of a payout Novella could earn.

Quintiles' headquarters    Quintiles' headquarters

October 31, 2013

Premium Lock Durham-based lab testing firm adding gear, people, space

BioAgilytix Labs, a fast-growing Durham laboratory providing contract testing for pharmaceutical, biotechnology and agricultural companies, has added new testing devices, more people, and is planning more space.

BioAgilytix BioAgilytix

Updated October 31, 2013

Premium Lock Quintiles' president resigning for 'personal' reasons; stock drops

John Ratliff John Ratliff, president and chief operating officer at Quintiles, has resigned, the company said early Thursday. Ratliff also is quitting as a member of the board.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith


Dr. Mike Walden
Tech economy
Vivek Wadhwa
Frank Vinluan
Life science